Blueprint Medicines (BPMC) PT Raised to $106 at Raymond James on Pralsetinib Deal
Tweet Send to a Friend
Raymond James analyst Dane Leone raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $106.00 (from $95.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
